Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam

Journal of Global Antimicrobial Resistance

Volumn 9, Issue , 2017, Pages 100-102

  Castaldo, Nadia ^a   Givone, Filippo ^a   Peghin, Maddalena ^a   Righi, Elda ^a   Sartor, Assunta ^a   Bassetti, Matteo ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Ceftolozane tazobactam; MDR; Multidrug resistance; Pseudomonas aeruginosa; Skin and soft tissue infection

Indexed keywords

CEFTOLOZANE PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; TAZOBACTAM;

AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; EMERGENCY WARD; FEMALE; HOSPITAL ADMISSION; HUMAN; KIDNEY FUNCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; SOFT TISSUE INFECTION; SURGICAL DRAINAGE; BACTERIAL SKIN DISEASE; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOLOGY; PSEUDOMONAS AERUGINOSA; TREATMENT OUTCOME; VERY ELDERLY;

AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TAZOBACTAM; TREATMENT OUTCOME;

EID: 85019134830     PISSN: 22137165     EISSN: 22137173     Source Type: Journal    
DOI: 10.1016/j.jgar.2017.02.012     Document Type: Article

References (12)

1. Pfaller, M.A., Bassetti, M., Duncan, L.R., Castanheira, M., Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–2015). J Antimicrob Chemother(February), 2017, 10.1093/jac/dkx009 Epub ahead of print.
2. Liscio, J.L., Mahoney, M.V., Hirsch, E.B., Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant gram-negative bacterial infections. Int J Antimicrob Agents 46 (2015), 266–271.
3. Flynt, L.K., Veve, M.P., Samuel, L.P., Tibbetts, R.J., Comparison of Etest to broth microdilution for testing of susceptibility of Pseudomonas aeruginosa to ceftolozane–tazobactam. J Clin Microbiol 55 (2016), 334–335.
4. Nathwani, D., Raman, G., Sulham, K., Gavaghan, M., Menon, V., Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control, 3, 2014, 32.
5. Aloush, V., Navon-Venezia, S., Seigman-Igra, Y., Cabili, S., Carmeli, Y., Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 50 (2006), 43–48.
6. Perez, F., Bonomo, R.A., Editorial commentary: bloodstream infection caused by extended-spectrum β-lactamase-producing gram-negative bacteria: how to define the best treatment regimen?. Clin Infect Dis 60 (2015), 1326–1329.
7. Sorbera, M., Chung, E., Ho, C.W., Marzella, N., Ceftolozane/tazobactam: a new option in the treatment of complicated gram-negative infections. P T 39 (2014), 825–832.
8. Wagenlehner, F.M., Umeh, O., Steenbergen, J., Yuan, G., Darouiche, R.O., Ceftolozane–tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385 (2015), 1949–1956.
9. Giancola, S.E., Mahoney, M.V., Bias, T.E., Hirsch, E.B., Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections. Ther Clin Risk Manag 12 (2016), 787–797.
10. Zhanel, G.G., Chung, P., Adam, H., Zelenitsky, S., Denisuik, A., Schweizer, F., et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs 74 (2014), 31–51.
11. Scott, L.J., Ceftolozane/tazobactam: a review in complicated intra-abdominal and urinary tract infections. Drugs 76 (2016), 231–242.
12. Sousa Dominguez, A., Perez-Rodríguez, M.T., Nodar, A., Martinez-Lamas, L., Perez-Landeiro, A., Crespo Casal, M., Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam. J Antimicrob Chemother 72 (2017), 1262–1263.